Caris Life Sciences® (NASDAQ: CAI) has published peer-reviewed clinical validation data in Oncotarget for MI Cancer Seek®, an FDA-approved companion diagnostic test designed to guide precision oncology treatments in both adults and pediatric patients.
Comprehensive Tumor Profiling via WES and WTS
MI Cancer Seek uniquely integrates whole exome sequencing (WES) and whole transcriptome sequencing (WTS) in a single assay—supporting one pan-cancer and five tumor-specific indications. The study demonstrated high analytical accuracy with positive and negative percent agreement rates ranging from 97% to 100% compared to other FDA-authorized companion diagnostics.
This dual-DNA/RNA testing approach enables robust detection from minimal tissue samples, reducing the need for separate extractions and potentially shortening diagnostic timelines.
Strengthening Clinical Confidence
“MI Cancer Seek provides a comprehensive molecular blueprint that saves tissue without compromising results,” stated David Spetzler, President of Caris. “These findings underscore our commitment to scientific rigor in molecular profiling.”
George W. Sledge Jr., CMO at Caris, added, “By integrating CDx tests into multi-gene panels, we can reduce inefficiencies and help more patients access personalized therapies.”
Leave a Comment